2.68
price down icon2.90%   -0.08
after-market アフターアワーズ: 2.73 0.05 +1.87%
loading
前日終値:
$2.76
開ける:
$2.81
24時間の取引高:
1.28M
Relative Volume:
1.05
時価総額:
$305.19M
収益:
$12.32M
当期純損益:
$-175.72M
株価収益率:
-1.235
EPS:
-2.17
ネットキャッシュフロー:
$-141.45M
1週間 パフォーマンス:
-1.47%
1か月 パフォーマンス:
-16.77%
6か月 パフォーマンス:
-33.99%
1年 パフォーマンス:
+12.13%
1日の値動き範囲:
Value
$2.495
$2.81
1週間の範囲:
Value
$2.27
$2.81
52週間の値動き範囲:
Value
$1.91
$8.83

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1181)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
181
Name
Twitter
@fatethx
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
Nov 04, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 04, 2024
pulisher
Oct 25, 2024

Fate Therapeutics Drops To US$2.81, Yet Insiders May Have Sold Too Early - Simply Wall St

Oct 25, 2024
pulisher
Oct 22, 2024

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionFATE - AsiaOne

Oct 22, 2024
pulisher
Oct 17, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 5.7% in September - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Fate Therapeutics Inc (FATE) looking to reclaim success with recent performance - SETE News

Oct 16, 2024
pulisher
Oct 15, 2024

Was Fate Therapeutics Inc (FATE)’s session last reading good? - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Market Recap Check: Fate Therapeutics Inc (FATE)’s Positive Finish at 3.09, Up/Down 5.10 - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from Analysts - MarketBeat

Oct 14, 2024
pulisher
Oct 09, 2024

Fate Therapeutics Inc [FATE] stock was sold by Xu Yuan at the price of US$2678.0 - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

Dimensional Fund Advisors LP Has $6.99 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

Holdings of Fate Therapeutics Inc (FATE) are aligned with the stars - SETE News

Oct 08, 2024
pulisher
Oct 08, 2024

Fate Therapeutics Inc (FATE) Stock: Heads Or Tails? - Stocks Register

Oct 08, 2024
pulisher
Oct 07, 2024

The Fate Therapeutics Inc (FATE) Stock Is Headed for a Correction - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Market Insight: Fate Therapeutics Inc (FATE)’s Notable Gain, Closing at 3.22 - The Dwinnex

Oct 07, 2024
pulisher
Oct 04, 2024

Renaissance Technologies LLC Takes Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Fate Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle

Oct 03, 2024
pulisher
Oct 02, 2024

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 02, 2024
pulisher
Oct 01, 2024

Can you still get a good price for Fate Therapeutics Inc (FATE) Shares at this point? - US Post News

Oct 01, 2024
pulisher
Sep 30, 2024

Fate Therapeutics' SWOT analysis: cell therapy stock poised for pivotal year - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Investor’s Toolkit: Key Ratios for Assessing Fate Therapeutics Inc (FATE)’s Performance - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Purchases New Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

You might want to take a look at Fate Therapeutics Inc (FATE) now - SETE News

Sep 30, 2024
pulisher
Sep 26, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Holdings Lifted by Deerfield Management Company L.P. Series C - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

FATE’s Debt-to-Equity Ratio at 0.25: What It Means for Fate Therapeutics Inc’s Future - The InvestChronicle

Sep 25, 2024
pulisher
Sep 24, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bumble Inc. - GlobeNewswire

Sep 24, 2024
pulisher
Sep 24, 2024

Fate Trigger The Novita Cinematic Teaser - GameSpot

Sep 24, 2024
pulisher
Sep 24, 2024

FTR: Trailer orders remain below expectations - Fleet Equipment Magazine

Sep 24, 2024
pulisher
Sep 24, 2024

Should investors be concerned about Fate Therapeutics Inc (FATE)? - US Post News

Sep 24, 2024
pulisher
Sep 23, 2024

FendX Provides Corporate Update - Newsfile

Sep 23, 2024
pulisher
Sep 23, 2024

Closing Figures: Fate Therapeutics Inc (FATE)’s Negative Finish at 3.87, Down -3.25 - The Dwinnex

Sep 23, 2024
pulisher
Sep 23, 2024

Integral Health Asset Management LLC Acquires 650,000 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Sep 23, 2024
pulisher
Sep 21, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Acquired by Bank of New York Mellon Corp - Defense World

Sep 21, 2024
pulisher
Sep 19, 2024

FTR reports August 2024 trailer orders were below projections - Trucks, Parts, Service

Sep 19, 2024
pulisher
Sep 19, 2024

Kaskela Law LLC Announces Shareholder Investigation of Fate - GlobeNewswire

Sep 19, 2024
pulisher
Sep 19, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.90 Consensus Price Target from Brokerages - MarketBeat

Sep 19, 2024
pulisher
Sep 18, 2024

Top investors say Fate Therapeutics Inc (FATE) ticks everything they need - SETE News

Sep 18, 2024
pulisher
Sep 18, 2024

E Fund Management Co. Ltd. Increases Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Sep 18, 2024
pulisher
Sep 17, 2024

Technical analysis of Fate Therapeutics Inc (FATE) stock chart patterns - US Post News

Sep 17, 2024
pulisher
Sep 16, 2024

Bruce & Co. Inc. Has $984,000 Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Sep 16, 2024
pulisher
Sep 12, 2024

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference - GlobeNewswire

Sep 12, 2024
pulisher
Sep 12, 2024

Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? - Yahoo Finance

Sep 12, 2024
pulisher
Sep 12, 2024

Acadian Asset Management LLC Increases Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Sep 12, 2024
pulisher
Sep 12, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Stake Lifted by Acadian Asset Management LLC - Defense World

Sep 12, 2024
pulisher
Sep 10, 2024

Are Smart Investors Making the Right Decision? Fate Therapeutics Inc (FATE) - SETE News

Sep 10, 2024
pulisher
Sep 09, 2024

Examining Fate Therapeutics Inc (FATE) more closely is necessary - US Post News

Sep 09, 2024
pulisher
Sep 09, 2024

Financial Analysis: Fate Therapeutics Inc (FATE)’s Ratios Unveil Key Insights - The Dwinnex

Sep 09, 2024
pulisher
Sep 05, 2024

There is no way Fate Therapeutics Inc (FATE) can keep these numbers up - SETE News

Sep 05, 2024
pulisher
Sep 04, 2024

FATE underperforms with a -5.99 decrease in share price - US Post News

Sep 04, 2024
pulisher
Sep 03, 2024

Deeper Dive: Understanding Fate Therapeutics Inc (FATE) Through its Various Ratios - The Dwinnex

Sep 03, 2024
pulisher
Sep 03, 2024

Bone Degeneration Therapeutics Market Outlook, Growth By Top - openPR

Sep 03, 2024

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):